Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

UK statisticians and trialists reach out to the clinical trial community in an awareness-raising paper published this week as a first step in changing practice. They promote the use of adaptive designs in early-phase clinical trials to improve trial efficiency, which will benefit patients.

Human clinical trials should be based on the best possible evidence. However, changing the design used in early-phase trials has proved challenging, even when newer methods increase the chance that the trial will get the correct answer. The NIHR Statisticians Research Group on Early Phase Clinical Trials, which includes CSM statisticians, is on a mission to help clinical trialists to underpin their phase I trials with best-practice designs. They target clinicians, nurses and statisticians in an open-access motivational awareness-raising paper published in the British Journal of Cancer this week.    

The first time a promising new medical treatment leaves the laboratory and is tested in a person is in a phase I dose-finding trial. These trials give a series of human participants different doses of the drug to find out which doses are not too toxic for humans. 

Phase I trials typically use rules set before the trial starts to decide what dose each participant gets. However, 20 years of statistics research has overwhelmingly shown that it is better to use mathematical models that decide each participant’s dose using the information gathered in the trial up until that participant. Although pharmaceutical companies have switched to using these models, academic trials still tend to use rules. Only 6.7% of all dose-finding trials use best-practice model-based designs!

CSM’s Sharon Love is a member of the NIHR Statisticians Research Group and a co-author on the motivational paper. She says, “This is the start of a concerted effort by UK statisticians and trialists using these designs to make them accessible to all. This first paper explains the benefits of using model-based designs and how to overcome barriers to using them. In collaboration with the MRC Network of Hubs for Trials Methodology Research's Adaptive Designs Working Group, we have submitted a second paper that will take readers through each step of the design of model-based design using non-statistical language.”     

The NIHR Statisticians Research Group plans to offer courses in 2018 to train trialists in using model-based designs for phase I trials. As these best-practice methods are used by the trials research community, the Group plans to conduct methodology research on the challenges that trialists discover when using these methods.

Similar stories

Clinical trial finds Azithromycin has no benefit against COVID-19

Main OCTRU

A clinical trial by University of Oxford researchers has confirmed that the antibiotic azithromycin has no clinical benefit in people with moderate COVID-19.

Study reveals the three most important aspects of care for hip fractures

Hip Main OCTRU Research Trauma

Older patients with hip fractures recover better if they receive treatment under the supervision of both a surgeon and a specialist in elderly care; are checked to avoid future falls; and are assessed for memory problems.

Major ERC funding awarded to Professor Michael Dustin

Awards Kennedy Main

Professor Michael Dustin and an international team of collaborators have been awarded a €10M grant from the European Research Council (ERC) to develop a new biotechnology around supramolecular attack particles (SMAPs) engineered to kill cancer cells.

The role of mAbs (neutralising monoclonal antibodies) in the fight against COVID-19

Main Research

Neutralising mAbs, a form of anti-viral medicine, are being explored as an attractive option to treat symptoms of COVID-19 and in some cases prevent infection. But what are the pros and cons of this type of treatment and what should regulators consider before granting approval?

Professor Michael Dustin elected to the National Academy of Sciences

Awards Kennedy Main

Recognised for his outstanding contributions to the field of immunology, Michael becomes the fourth Kennedy professor to be elected to the Academy.

Small mechanical forces in immune cells measured at unprecedented sensitivity

Kennedy Main Research

Oxford researchers have used advanced microscopy techniques to measure previously unseen forces generated by cells during an immune response; a breakthrough for mechanobiology and future advances in health and disease.